Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07605806 · ClinicalTrials.gov registry record · Phase 1
Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions
A Phase 1 study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT07605806: Recruiting Phase 1 study, sponsored by Johns Hopkins University.
NCT07605806 is a Phase 1 study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07605806, a Phase 1 study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to investigate biomarkers of non-IgE-mediated immediate hypersensitivity reactions during infusion of intravenous vancomycin. The main question it aims to answer is: • Identifying novel biomarkers in blood that occur during infusion reaction Participants will: * Have allergy skin testing for vancomycin * Receive an infusion of vancomycin
Interventions
- DRUG Vancomycin (IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07605806
The ClinicalTrials.gov registry entry for NCT07605806 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vancomycin (IV) is the first listed.
NCT07605806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07605806 about?
NCT07605806 is a clinical study titled "Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions". The goal of this clinical trial is to investigate biomarkers of non-IgE-mediated immediate hypersensitivity reactions during infusion of intravenous vancomycin. The main question it aims to answer is: • Identifying novel biomarkers in blood that occur during infusion reaction Participants will: *...
What is the current status of trial NCT07605806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2026-05-21. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07605806?
The interventions under investigation include: Vancomycin (IV) (DRUG).
Who is sponsoring clinical trial NCT07605806?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.